BACKGROUND AND METHODS. Gaucher's disease, the most prevalent of the sphingolipid storage disorders, is caused by a deficiency of the enzyme glucocerebrosidase (glucosylceramidase). Enzyme replacement was proposed as a therapeutic strategy for this disorder in 1966. To assess the clinical effectiveness of this approach, we infused macrophage-targeted human placental glucocerebrosidase (60 IU per kilogram of body weight every 2 weeks for 9 to 12 months) into 12 patients with type 1 Gaucher's disease who had intact spleens. The frequency of infusions was increased to once a week in two patients (children) during part of the trial because they had clinically aggressive disease. RESULTS. The hemoglobin concentration increased in all 12 patients, and the platelet count in 7. Serum acid phosphatase activity decreased in 10 patients during the trial, and the plasma glucocerebroside level in 9. Splenic volume decreased in all patients after six months of treatment, and hepatic volume in five. Early signs of skeletal improvements were seen in three patients. The enzyme infusions were well tolerated, and no antibody to the exogenous enzyme developed. CONCLUSIONS. Intravenous administration of macrophage-targeted glucocerebrosidase produces objective clinical improvement in patients with type 1 Gaucher's disease. The hematologic and visceral responses to enzyme replacement develop more rapidly than the skeletal response.
Source Information
Departmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
This article has been cited by other articles:
Du, H., Cameron, T. L., Garger, S. J., Pogue, G. P., Hamm, L. A., White, E., Hanley, K. M., Grabowski, G. A.
(2008). Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J. Lipid Res.
49: 1646-1657
[Abstract][Full Text]
DeMayo, R. F., Haims, A. H., McRae, M. C., Yang, R., Mistry, P. K.
(2008). Correlation of MRI-Based Bone Marrow Burden Score with Genotype and Spleen Status in Gaucher's Disease. Am. J. Roentgenol.
191: 115-123
[Abstract][Full Text]
Tomatsu, S., Montano, A. M., Ohashi, A., Gutierrez, M. A., Oikawa, H., Oguma, T., Dung, V. C., Nishioka, T., Orii, T., Sly, W. S.
(2008). Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet
17: 815-824
[Abstract][Full Text]
Enquist, I. B., Bianco, C. L., Ooka, A., Nilsson, E., Mansson, J.-E., Ehinger, M., Richter, J., Brady, R. O., Kirik, D., Karlsson, S.
(2007). Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. USA
104: 17483-17488
[Abstract][Full Text]
Elstein, D., Dweck, A., Attias, D., Hadas-Halpern, I., Zevin, S., Altarescu, G., Aerts, J. F. M. G., van Weely, S., Zimran, A.
(2007). Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood
110: 2296-2301
[Abstract][Full Text]
Zheng, W., Padia, J., Urban, D. J., Jadhav, A., Goker-Alpan, O., Simeonov, A., Goldin, E., Auld, D., LaMarca, M. E., Inglese, J., Austin, C. P., Sidransky, E.
(2007). Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc. Natl. Acad. Sci. USA
104: 13192-13197
[Abstract][Full Text]
Akeboshi, H., Chiba, Y., Kasahara, Y., Takashiba, M., Takaoka, Y., Ohsawa, M., Tajima, Y., Kawashima, I., Tsuji, D., Itoh, K., Sakuraba, H., Jigami, Y.
(2007). Production of Recombinant {beta}-Hexosaminidase A, a Potential Enzyme for Replacement Therapy for Tay-Sachs and Sandhoff Diseases, in the Methylotrophic Yeast Ogataea minuta. Appl. Environ. Microbiol.
73: 4805-4812
[Abstract][Full Text]
Robertson, P. L., Maas, M., Goldblatt, J.
(2007). Semiquantitative Assessment of Skeletal Response to Enzyme Replacement Therapy for Gaucher's Disease Using the Bone Marrow Burden Score. Am. J. Roentgenol.
188: 1521-1528
[Abstract][Full Text]
Van Patten, S. M., Hughes, H., Huff, M. R., Piepenhagen, P. A., Waire, J., Qiu, H., Ganesa, C., Reczek, D., Ward, P. V., Kutzko, J. P., Edmunds, T.
(2007). Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology
17: 467-478
[Abstract][Full Text]
Groener, J. E.M., Poorthuis, B. J.H.M., Kuiper, S., Helmond, M. T.J., Hollak, C. E.M., Aerts, J. M.F.G.
(2007). HPLC for Simultaneous Quantification of Total Ceramide, Glucosylceramide, and Ceramide Trihexoside Concentrations in Plasma. Clin. Chem.
53: 742-747
[Abstract][Full Text]
Schmitz, J., Poll, L. W., Dahl, S. v.
(2007). Therapy of adult Gaucher disease. haematol
92: 148-152
[Full Text]
de Fost, M., Aerts, J. M.F.G., Groener, J. E.M., Maas, M., Akkerman, E. M., Wiersma, M. G., Hollak, C. E.M.
(2007). Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. haematol
92: 215-221
[Abstract][Full Text]
Lonser, R. R., Schiffman, R., Robison, R. A., Butman, J. A., Quezado, Z., Walker, M. L., Morrison, P. F., Walbridge, S., Murray, G. J., Park, D. M., Brady, R. O., Oldfield, E. H.
(2007). Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology
68: 254-261
[Abstract][Full Text]
Enquist, I. B., Nilsson, E., Ooka, A., Mansson, J.-E., Olsson, K., Ehinger, M., Brady, R. O., Richter, J., Karlsson, S.
(2006). Effective cell and gene therapy in a murine model of Gaucher disease. Proc. Natl. Acad. Sci. USA
103: 13819-13824
[Abstract][Full Text]
Parkinson-Lawrence, E., Fuller, M., Hopwood, J. J., Meikle, P. J., Brooks, D. A.
(2006). Immunochemistry of Lysosomal Storage Disorders. Clin. Chem.
52: 1660-1668
[Abstract][Full Text]
de Fost, M., Hollak, C. E. M., Groener, J. E. M., Aerts, J. M. F. G., Maas, M., Poll, L. W., Wiersma, M. G., Haussinger, D., Brett, S., Brill, N., Dahl, S. v.
(2006). Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood
108: 830-835
[Abstract][Full Text]
Kaplan, P., Andersson, H. C., Kacena, K. A., Yee, J. D.
(2006). The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at Diagnosis. Arch Pediatr Adolesc Med
160: 603-608
[Abstract][Full Text]
Oheda, Y., Kotani, M., Murata, M., Sakuraba, H., Kadota, Y., Tatano, Y., Kuwahara, J., Itoh, K.
(2006). Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement. Glycobiology
16: 271-280
[Abstract][Full Text]
Brautbar, A., Elstein, D., Pines, B., Krienen, N., Hemmer, J., Buskila, D., Zimran, A.
(2006). Fibromyalgia and Gaucher's disease. QJM
99: 103-107
[Abstract][Full Text]
Fuller, M., Lovejoy, M., Hopwood, J. J., Meikle, P. J.
(2005). Immunoquantification of {beta}-Glucosidase: Diagnosis and Prediction of Severity in Gaucher Disease. Clin. Chem.
51: 2200-2202
[Full Text]
LeBowitz, J. H.
(2005). A breach in the blood-brain barrier. Proc. Natl. Acad. Sci. USA
102: 14485-14486
[Full Text]
Ioscovich, A., Briskin, A., Abrahamov, A., Halpern, S., Zimran, A., Elstein, D.
(2005). Uncomplicated outcome after anesthesia for pediatric patients with Gaucher disease: [Evolution sans complications apres l'anesthesie de patients pediatriques atteints de la maladie de Gaucher]. Canadian J. Anesthesia
52: 845-847
[Abstract][Full Text]
Rosenbloom, B. E., Weinreb, N. J., Zimran, A., Kacena, K. A., Charrow, J., Ward, E.
(2005). Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood
105: 4569-4572
[Abstract][Full Text]
Matzner, U., Herbst, E., Hedayati, K. K., Lullmann-Rauch, R., Wessig, C., Schroder, S., Eistrup, C., Moller, C., Fogh, J., Gieselmann, V.
(2005). Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet
14: 1139-1152
[Abstract][Full Text]
Roces, D. P., Lullmann-Rauch, R., Peng, J., Balducci, C., Andersson, C., Tollersrud, O., Fogh, J., Orlacchio, A., Beccari, T., Saftig, P., von Figura, K.
(2004). Efficacy of enzyme replacement therapy in {alpha}-mannosidosis mice: a preclinical animal study. Hum Mol Genet
13: 1979-1988
[Abstract][Full Text]
Wenstrup, R. J., Bailey, L., Grabowski, G. A., Moskovitz, J., Oestreich, A. E., Wu, W., Sun, S.
(2004). Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood
104: 1253-1257
[Abstract][Full Text]
LeBowitz, J. H., Grubb, J. H., Maga, J. A., Schmiel, D. H., Vogler, C., Sly, W. S.
(2004). Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA
101: 3083-3088
[Abstract][Full Text]
Dhami, R., Schuchman, E. H.
(2004). Mannose 6-Phosphate Receptor-mediated Uptake Is Defective in Acid Sphingomyelinase-deficient Macrophages: IMPLICATIONS FOR NIEMANN-PICK DISEASE ENZYME REPLACEMENT THERAPY. J. Biol. Chem.
279: 1526-1532
[Abstract][Full Text]
Mariani, G., Filocamo, M., Giona, F., Villa, G., Amendola, A., Erba, P., Buffoni, F., Copello, F., Pierini, A., Minichilli, F., Gatti, R., Brady, R. O.
(2003). Severity of Bone Marrow Involvement in Patients with Gaucher's Disease Evaluated by Scintigraphy with 99mTc-Sestamibi. JNM
44: 1253-1262
[Abstract][Full Text]
Larsen, E. C., Connolly, S. A., Rosenberg, A. E.
(2003). Case 20-2003 - A Nine-Year-Old Girl with Hepatosplenomegaly and Pain in the Thigh. NEJM
348: 2669-2677
[Full Text]
Dayan, B., Elstein, D., Zimran, A., Nesher, G.
(2003). Decreased salivary output in patients with Gaucher disease. QJM
96: 53-56
[Abstract][Full Text]
Chiba, Y., Sakuraba, H., Kotani, M., Kase, R., Kobayashi, K., Takeuchi, M., Ogasawara, S., Maruyama, Y., Nakajima, T., Takaoka, Y., Jigami, Y.
(2002). Production in yeast of {alpha}-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology
12: 821-828
[Abstract][Full Text]
Patlas, M., Hadas-Halpern, I., Reinus, C., Zimran, A., Elstein, D.
(2002). Multiple Hypoechoic Hepatic Lesions in a Patient With Gaucher Disease. J Ultrasound Med
21: 1053-1055
[Full Text]
Poll, L W, Maas, M, Terk, M R, Roca-Espiau, M, Bembi, B, Ciana, G, Weinreb, N J
(2002). Response of Gaucher bone disease to enzyme replacement therapy. Br. J. Radiol.
75: A25-36
[Abstract][Full Text]
Bembi, B, Ciana, G, Mengel, E, Terk, M R, Martini, C, Wenstrup, R J
(2002). Bone complications in children with Gaucher disease. Br. J. Radiol.
75: A37-44
[Abstract][Full Text]
Sly, W. S., Vogler, C.
(2002). Brain-directed gene therapy for lysosomal storage disease: Going well beyond the blood- brain barrier. Proc. Natl. Acad. Sci. USA
99: 5760-5762
[Full Text]
Sands, M. S., Vogler, C. A., Ohlemiller, K. K., Roberts, M. S., Grubb, J. H., Levy, B., Sly, W. S.
(2001). Biodistribution, Kinetics, and Efficacy of Highly Phosphorylated and Non-phosphorylated beta -Glucuronidase in the Murine Model of Mucopolysaccharidosis VII. J. Biol. Chem.
276: 43160-43165
[Abstract][Full Text]
Du, H., Schiavi, S., Levine, M., Mishra, J., Heur, M., Grabowski, G. A.
(2001). Enzyme therapy for lysosomal acid lipase deficiency in the mouse. Hum Mol Genet
10: 1639-1648
[Abstract][Full Text]
Goitein, O., Elstein, D., Abrahamov, A., Hadas-Halpern, I., Melzer, E., Kerem, E., Zimran, A.
(2001). Lung involvement and enzyme replacement therapy in Gaucher's disease. QJM
94: 407-415
[Abstract][Full Text]
Mankin, H. J., Rosenthal, D. I., Xavier, R.
(2001). Gaucher Disease : New Approaches to an Ancient Disease. JBJS
83: 748-763
[Full Text]
Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., Hoft, R., Neufeld, E. F.
(2001). Enzyme-Replacement Therapy in Mucopolysaccharidosis I. NEJM
344: 182-188
[Abstract][Full Text]
Brady, R. O., Schiffmann, R.
(2000). Clinical Features of and Recent Advances in Therapy for Fabry Disease. JAMA
284: 2771-2775
[Abstract][Full Text]
Fabrega, S., Durand, P., Codogno, P., Bauvy, C., Delomenie, C., Henrissat, B., Martin, B. M., McKinney, C., Ginns, E. I., Mornon, J.-P., Lehn, P.
(2000). Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells. Glycobiology
10: 1217-1224
[Abstract][Full Text]
MIRANDA, S. R. P., HE, X., SIMONARO, C. M., GATT, S., DAGAN, A., DESNICK, R. J., SCHUCHMAN, E. H.
(2000). Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J.
14: 1988-1995
[Abstract][Full Text]
DUNDER, U., KAARTINEN, V., VALTONEN, P., VÄÄNÄNEN, E., KOSMA, V.-M., HEISTERKAMP, N., GROFFEN, J., MONONEN, I.
(2000). Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J.
14: 361-367
[Abstract][Full Text]
Brady, R. O.
(2000). Neurogene Therapy for the 21st Century. Arch Neurol
57: 54-54
[Full Text]
Amalfitano, A., McVie-Wylie, A. J., Hu, H., Dawson, T. L., Raben, N., Plotz, P., Chen, Y. T.
(1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha -glucosidase. Proc. Natl. Acad. Sci. USA
96: 8861-8866
[Abstract][Full Text]
Friedman, B., Vaddi, K., Preston, C., Mahon, E., Cataldo, J. R., McPherson, J. M.
(1999). A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived beta -Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease. Blood
93: 2807-2816
[Abstract][Full Text]
Rosenberg, M., Kingma, W., Fitzpatrick, M. A., Richards, S. M.
(1999). Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration. Blood
93: 2081-2088
[Abstract][Full Text]
Charrow, J., Esplin, J. A., Gribble, T. J., Kaplan, P., Kolodny, E. H., Pastores, G. M., Scott, C. R., Wappner, R. S., Weinreb, N. J., Wisch, J. S.
(1998). Gaucher Disease: Recommendations on Diagnosis, Evaluation, and Monitoring. Arch Intern Med
158: 1754-1760
[Abstract][Full Text]
Brady, R. O.
(1998). Therapy for the Sphingolipidoses. Arch Neurol
55: 1055-1056
[Abstract][Full Text]
Krasnewich, D., Dietrich, K., Bauer, L., Ginns, E. I., Sidransky, E., Hill, S.
(1998). Splenectomy in Gaucher Disease: New Management Dilemmas. Blood
91: 3085-3087
[Full Text]
Henin, O., Boustta, M., Domurado, M., Coudane, J., Domurado, D., Vert, M.
(1998). Covalent Binding of Mannosyl Ligand via 6-O Position and Glycolic Arm to Target a PLCA-Type Degradable Drug Carrier toward Macrophages. Journal of Bioactive and Compatible Polymers
13: 19-32
[Abstract]
Brady, R. O., Murray, G. J., Oliver, K. L., Leitman, S. F., Sneller, M. C., Fleisher, T. A., Barton, N. W., Collaborators,
(1997). Management of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher Disease. Pediatrics
100: e11-e11
[Abstract][Full Text]
Ciana, G., Cuttini, M., Bembi, B.
(1997). Short-Term Effects of Pamidronate in Patients with Gaucher's Disease and Severe Skeletal Involvement. NEJM
337: 712-712
[Full Text]
Kennedy, D. W., Abkowitz, J. L.
(1997). Kinetics of Central Nervous System Microglial and Macrophage Engraftment: Analysis Using a Transgenic Bone Marrow Transplantation Model. Blood
90: 986-993
[Abstract][Full Text]
Ponce, E., Moskovitz, J., Grabowski, G.
(1997). Enzyme Therapy in Gaucher Disease Type 1: Effect of Neutralizing Antibodies to Acid beta -Glucosidase. Blood
90: 43-48
[Abstract][Full Text]
Lorincz, M., Herzenberg, L. A., Diwu, Z., Barranger, J. A., Kerr, W. G.
(1997). Detection and Isolation of Gene-Corrected Cells in Gaucher Disease Via a Fluorescence-Activated Cell Sorter Assay for Lysosomal Glucocerebrosidase Activity. Blood
89: 3412-3420
[Abstract][Full Text]
Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A., Butters, T. D.
(1997). Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin. Science
276: 428-431
[Abstract][Full Text]
Cerneca, F., Andolina, M., Simeone, R., Boscolo, R., Ciana, G., Bembi, B.
(1997). Treatment of Patients wIth Niemann-Pick Type Is Using Repeated Amniotic Epithelial Cells Implantation: Correction of Aggregation and Coagulation Abnormalities. CLIN PEDIATR
36: 141-146
[Abstract]
Roth, K. S.
(1997). Enzyme Replacement Therapy. CLIN PEDIATR
36: 147-148
Sidransky, E., Tayebi, N., Ginns, E. I.
(1995). Diagnosing Gaucher Disease: Early Recognition, Implications for Treatment, and Genetic Counseling. CLIN PEDIATR
34: 365-371
[Abstract]
Renkema, G. H., Boot, R. G., Muijsers, A. O., Donker-Koopman, W. E., Aerts, J. M. F. G.
(1995). Purification and Characterization of Human Chitotriosidase, a Novel Member of the Chitinase Family of Proteins. J. Biol. Chem.
270: 2198-2202
[Abstract][Full Text]
Moscicki, R. A., Taunton-Rigby, A., Barton, N. W., Brady, R. O., Dambrosia, J. M., Grabowski, G. A., Hollak, C. E.M., Aerts, J.M.F.G., van Oers, M.H.J., Sidransky, E., Martin, B., Ginns, E. I., Freiwald, D. R., Lexchin, J., Beutler, E., Figueroa, M., Koziol, J., Garber, A. M.
(1993). Treatment of Gaucher's Disease. NEJM
328: 1564-1568
[Full Text]
Beutler, E
(1992). Gaucher disease: new molecular approaches to diagnosis and treatment. Science
256: 794-799
[Abstract]
Previous
